{
    "data": [
        {
            "id": "1041891",
            "type": "article",
            "attributes": {
                "publishOn": "2012-12-03T14:34:37-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Kalydeco Approval In Canada More Important To Patients Than To Vertex",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "35761",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1041891-kalydeco-approval-in-canada-more-important-to-patients-than-to-vertex"
            }
        },
        {
            "id": "1013351",
            "type": "article",
            "attributes": {
                "publishOn": "2012-11-16T07:22:14-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pessimism On Vertex Pharmaceuticals Increases, Erasing Previous Gains",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24433",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1013351-pessimism-on-vertex-pharmaceuticals-increases-erasing-previous-gains"
            }
        },
        {
            "id": "920911",
            "type": "article",
            "attributes": {
                "publishOn": "2012-10-12T12:04:54-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Gets Uneasy On Mixed Clinical Trial Results",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24433",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "107079",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/920911-vertex-gets-uneasy-on-mixed-clinical-trial-results"
            }
        },
        {
            "id": "770361",
            "type": "article",
            "attributes": {
                "publishOn": "2012-08-01T14:17:52-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex's Cystic Fibrosis Pipeline Offers Sales Upside",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23407",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "104401",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/770361-vertexs-cystic-fibrosis-pipeline-offers-sales-upside"
            }
        },
        {
            "id": "707861",
            "type": "article",
            "attributes": {
                "publishOn": "2012-07-09T03:51:25-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why You Should Be Bullish On Vertex Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25901",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/707861-why-you-should-be-bullish-on-vertex-now"
            }
        },
        {
            "id": "622711",
            "type": "article",
            "attributes": {
                "publishOn": "2012-05-29T10:14:30-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex's Data Bungle Offers Entry Point",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25313",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "101875",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/622711-vertexs-data-bungle-offers-entry-point"
            }
        },
        {
            "id": "584321",
            "type": "article",
            "attributes": {
                "publishOn": "2012-05-13T04:31:35-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex's Cystic Fibrosis Drug Impresses Investors",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23087",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/584321-vertexs-cystic-fibrosis-drug-impresses-investors"
            }
        },
        {
            "id": "572611",
            "type": "article",
            "attributes": {
                "publishOn": "2012-05-09T04:26:10-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Cystic Fibrosis Data Defies Market Drop",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23407",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "101027",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/572611-vertex-cystic-fibrosis-data-defies-market-drop"
            }
        },
        {
            "id": "569361",
            "type": "article",
            "attributes": {
                "publishOn": "2012-05-08T11:19:36-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: Well-Equipped To Own The Future",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23183",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "100978",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/569361-vertex-well-equipped-to-own-the-future"
            }
        },
        {
            "id": "566811",
            "type": "article",
            "attributes": {
                "publishOn": "2012-05-07T15:55:03-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "5 Biotech Stocks With Massive Upside Potential In 2013",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "29161",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/566811-5-biotech-stocks-with-massive-upside-potential-in-2013"
            }
        },
        {
            "id": "566421",
            "type": "article",
            "attributes": {
                "publishOn": "2012-05-07T15:02:13-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: This Patent King Is The Stock Du Jour",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25159",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/566421-vertex-this-patent-king-is-the-stock-du-jour"
            }
        },
        {
            "id": "531851",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-26T14:07:48-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Finding Opportunity In Small Biotech Companies",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24063",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "100453",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/531851-finding-opportunity-in-small-biotech-companies"
            }
        },
        {
            "id": "527281",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-25T13:13:21-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Is Ready To Rise On Incivek Success",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25953",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "100396",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/527281-vertex-is-ready-to-rise-on-incivek-success"
            }
        },
        {
            "id": "491251",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-11T10:51:31-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: Watch New Hepatitis C Drug",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25032",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "99765",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/491251-vertex-watch-new-hepatitis-c-drug"
            }
        },
        {
            "id": "485421",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-09T11:30:35-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "4 Biotech Stocks Outperforming Vertex",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25901",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/485421-4-biotech-stocks-outperforming-vertex"
            }
        },
        {
            "id": "485291",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-09T10:58:59-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Has A Strong Pipeline For Profits",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25032",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "99638",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/485291-vertex-has-a-strong-pipeline-for-profits"
            }
        },
        {
            "id": "485131",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-09T10:28:20-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals Could See Strong Gains From Incivek",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25159",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/485131-vertex-pharmaceuticals-could-see-strong-gains-from-incivek"
            }
        },
        {
            "id": "463371",
            "type": "article",
            "attributes": {
                "publishOn": "2012-03-28T11:15:07-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy Vertex Pharmaceuticals: Expanding Franchises Are Undervalued",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24802",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "99185",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/463371-buy-vertex-pharmaceuticals-expanding-franchises-are-undervalued"
            }
        },
        {
            "id": "404691",
            "type": "article",
            "attributes": {
                "publishOn": "2012-03-01T11:21:29-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Recent FDA Approval Makes Vertex A Ripe Target For Takeover",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21798",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "98198",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/404691-recent-fda-approval-makes-vertex-a-ripe-target-for-takeover"
            }
        },
        {
            "id": "379641",
            "type": "article",
            "attributes": {
                "publishOn": "2012-02-21T09:34:15-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: The Best Of The Companies Investing In Cystic Fibrosis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25313",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "97884",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/379641-vertex-the-best-of-the-companies-investing-in-cystic-fibrosis"
            }
        },
        {
            "id": "331692",
            "type": "article",
            "attributes": {
                "publishOn": "2012-02-01T09:15:31-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharma's Latest FDA Approval Is Only The Beginning",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25268",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "97301",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/331692-vertex-pharmas-latest-fda-approval-is-only-the-beginning"
            }
        },
        {
            "id": "322685",
            "type": "article",
            "attributes": {
                "publishOn": "2012-01-27T12:14:55-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals Could See Huge Long-Term Gains",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25268",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "97174",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/322685-vertex-pharmaceuticals-could-see-huge-long-term-gains"
            }
        },
        {
            "id": "321131",
            "type": "article",
            "attributes": {
                "publishOn": "2012-01-22T10:13:48-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals: Great Pipeline, Valuation And Future",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24802",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "96989",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/321131-vertex-pharmaceuticals-great-pipeline-valuation-and-future"
            }
        },
        {
            "id": "319036",
            "type": "article",
            "attributes": {
                "publishOn": "2012-01-11T18:37:48-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: Resolutions For The New Year Should Be Shareholder Friendly",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23407",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "96731",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/319036-vertex-resolutions-for-the-new-year-should-be-shareholder-friendly"
            }
        }
    ]
}